Every 8-K that Owens & Minor, Inc. (OMI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMI filings page.
Accendra Health, Inc. has launched exchange offers and related consent solicitations for its outstanding 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders can swap these unsecured notes into newly issued 9.000% senior secured first lien notes due 2032 and 9.750% senior secured second lien notes due 2033, with different consideration levels depending on participation in a new money notes issuance and early tender deadlines. The company is also raising $326.25 million in new first lien notes for cash and seeking consents to strip most covenants and certain events of default from the existing indentures. Accendra notes the offers are subject to multiple conditions and warns that failing to complete these or alternative transactions on favorable terms could materially adversely affect its financial condition.
Accendra Health, Inc. reported results from its 2026 Annual Meeting of Shareholders. Shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan, which replaces the prior 2023 plan and allows the Board’s Our People & Culture Committee to grant equity and other incentive awards to employees, non-employee directors and consultants.
At the meeting, 76,437,917 shares were entitled to vote and 62,134,133 shares were voted, representing approximately 81.29% participation. Six director nominees each received over 48.7 million votes for, including 51,189,677 votes for Teresa L. Kline, with detailed vote counts and broker non-votes reported for all proposals.
Accendra Health is pursuing a comprehensive balance sheet overhaul built around new secured debt, note exchanges and amended bank facilities. The company agreed to offer $326.25 million of new 9.000% Senior Secured First Lien Notes due 2032, alongside exchange offers and consent solicitations for its existing 4.500% 2029 and 6.625% 2030 senior notes.
Certain noteholders and term loan lenders have committed, subject to conditions, to backstop $261.0 million of the new first lien notes and up to an additional $65.25 million, and to tender all of their existing notes in the exchanges. Revolving lenders have committed to a new $300.0 million revolving credit facility due 2030, and term lenders have agreed to consents and covenant changes, including waiving mandatory prepayments tied to $400.0 million of asset sale proceeds.
The company’s confidential investor deck highlights its post-divestiture profile as a pure‑play home‑based care platform with about $2.8 billion of FY2025 revenue, diversified chronic‑care exposure, and management’s projections for mid‑teens adjusted EBITDA margins, strong free‑cash‑flow generation and lower leverage after the transaction.
Accendra Health reported a first-quarter 2026 net loss from continuing operations of $6.5 million, or $0.08 per share, on net revenue of $627.8 million, down from $673.9 million a year earlier. Operating income was $17.1 million, but higher interest expense contributed to the loss.
Non-GAAP results weakened, with adjusted net loss of $3.1 million versus adjusted net income of $23.2 million and adjusted EBITDA of $58.4 million versus $96.0 million. Free cash flow turned slightly negative at $(2.0) million. Cash rose to $336.9 million, while net debt remained high at $1.77 billion.
The company also announced commitments from existing creditors for a more than $1.5 billion comprehensive balance sheet optimization transaction intended to extend debt maturities, reduce total leverage and reset its capital structure as it continues its shift to a pure play home-based care business.
Accendra Health, Inc. reported fourth-quarter and full-year 2025 results that reflect its shift to a standalone home-based care business after completing the sale of its Products & Healthcare Services business on December 31, 2025.
From continuing operations, net revenue rose to $708.967 million in Q4 2025 from $695.023 million a year earlier, with Q4 operating income improving to $20.9 million from a loss of $272.7 million. For 2025, continuing net revenue grew to $2.762 billion from $2.680 billion, and adjusted EBITDA was $374.847 million versus $370.515 million in 2024.
Despite better underlying performance, the company recorded a substantial full-year net loss of $1.1006 billion, driven largely by a $997.960 million loss from discontinued operations and an $80 million transaction breakage fee related to a terminated acquisition. Cash and cash equivalents increased markedly to $281.989 million at December 31, 2025, and net debt declined to $1.768 billion, while total equity moved to a deficit position. Management highlighted strong cash flow, ongoing cost controls and balance sheet optimization as it completes separation from Owens & Minor and focuses on sustainable growth.
Accendra Health, Inc., formerly Owens & Minor, Inc., filed an amended current report to update the financial information related to the previously completed sale of its P&HS business. The amendment is limited to revising Item 9.01 to include unaudited pro forma condensed financial information reflecting the impact of this transaction.
This pro forma information is provided as Exhibit 99.1 and is incorporated by reference, helping readers see how the company’s results would look after the P&HS business sale under the Equity Purchase Agreement with Dominion Healthcare entities. No other parts of the earlier closing report are changed.
Owens & Minor, Inc. completed the sale of its Products & Healthcare Services (P&HS) business to Dominion Healthcare for $375 million in cash, subject to adjustments, plus rollover equity in the buyer’s parent. The company also put in place an amended receivables sale program under which up to $150 million of accounts receivable can be sold on a limited‑recourse basis and accounted for as true sales, removing those receivables from its balance sheet. In connection with the divestiture, certain subsidiaries were released as guarantors under existing credit facilities and indentures, two senior executives departed, and the executive deferred compensation plan was amended for affected employees. The company is changing its corporate name to Accendra Health, Inc., with NYSE trading expected to begin under the new name and ticker “ACH” on January 2, 2026.
Owens & Minor, Inc. reports two key corporate actions. The board approved an amendment to the Owens & Minor Executive Deferred Compensation and Retirement Plan that will freeze participation and all contributions for all participants, effective January 1, 2026. This means executives already in the plan will not be able to make additional deferrals under this program after that date.
The company also plans a rebrand. It announced that it will change its name to Accendra Health, Inc. and that its New York Stock Exchange ticker symbol will change from “OMI” to “ACH.” The name change is anticipated to be effective on or about December 31, 2025, with trading under the new name and ticker expected to begin on or about January 2, 2026.
Owens & Minor, Inc. announced leadership changes focused on operations and human resources. Effective December 5, 2025, the company appointed Perry A. Bernocchi, age 67, as Executive Vice President and Chief Operating Officer. He has served since March 2023 as Executive Vice President and Chief Executive Officer of the company’s Patient Direct segment, and his compensation and employment terms remain unchanged.
The company also disclosed that Jennifer Stone, Executive Vice President and Chief Human Resources Officer, will leave effective December 31, 2025. Upon her departure, the CHRO position will be eliminated, and Heath Galloway, Executive Vice President, General Counsel & Corporate Secretary, will assume oversight of the human resources function in addition to his current responsibilities.
Owens & Minor, Inc. reported that its management team will participate in two upcoming investor conferences. The company has prepared an investor presentation specifically for the Bank of America Leveraged Finance Conference and has made both the related press release and the presentation available as exhibits. These materials are being furnished, not filed, which means they are provided for informational purposes and are not incorporated into other securities law filings unless specifically referenced.
Owens & Minor (OMI) furnished materials related to its results of operations. The company issued a press release covering financial results for the third quarter and nine months ended September 30, 2025, and made an earnings presentation available on its investor relations website.
Both documents were furnished, not filed, under Items 2.02 and 7.01, respectively, and are included as Exhibits 99.1 and 99.2. As furnished materials under General Instruction B.2, they are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
Owens & Minor, Inc. agreed to sell its Products & Healthcare Services business (O&M PHS LLC) to Dominion Healthcare Acquisition Corporation for $375,000,000 in cash, subject to customary adjustments for cash, indebtedness, net working capital and transaction expenses. As part of the transaction, Owens & Minor will receive non‑voting rollover interests in Purchaser Parent in exchange for certain company securities; those rollover interests pay 50% of distributions after Purchaser Parent has made aggregate distributions of $310 million until Owens & Minor receives $200 million, and 5% of distributions thereafter.
The Equity Purchase Agreement and a company press release are dated October 7, 2025. The filing states related SEC reports (Form 10‑K and Form 10‑Q for specified periods) and that the cover page XBRL tags are embedded in the Inline XBRL document.
Owens & Minor, Inc. reports that its Executive Vice President and Chief Information Officer, Snehashish Sarkar, has resigned from the company. He notified Owens & Minor on September 15, 2025 that he will leave his role effective September 26, 2025 to pursue another opportunity.
Sarkar has served as Chief Information Officer since October 2022. The company notes that during his tenure he built a strong global information technology team that is described as well-prepared to continue supporting Owens & Minor’s strategic priorities after his departure.
Owens & Minor, Inc. announced that it issued a press release reporting its financial results for the second quarter and for the six months ended June 30, 2025, and posted an earnings presentation on its Investor Relations website. The company furnished the press release as Exhibit 99.1, the earnings presentation as Exhibit 99.2, and included an Inline XBRL cover page as Exhibit 104. The 8-K states these materials are furnished under Item 2.02 and Item 7.01 and explicitly notes they are not "filed" for purposes of Section 18 of the Exchange Act. The numeric results and supporting slides are contained in the attached exhibits and on the company website rather than in the body of this filing.